# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Maxim Group analyst Anthony Vendetti maintains Nephros (NASDAQ:NEPH) with a Buy and raises the price target from $4.5 to $6.
Nephros (NASDAQ:NEPH) reported quarterly earnings of $0.02 per share which beat the analyst consensus estimate of $(0.03) by 18...